Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies
Forward TherapeuticsForward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing.